Ontology highlight
ABSTRACT:
SUBMITTER: Iaccarino L
PROVIDER: S-EPMC6562030 | biostudies-literature | 2019 Jun
REPOSITORIES: biostudies-literature
Annals of clinical and translational neurology 20190524 6
Imaging biomarkers can be used to screen participants for Alzheimer's disease clinical trials. To test the predictive values in clinical progression of neuropathology change (amyloid-PET) or brain metabolism as neurodegeneration biomarker ([18F]FDG-PET), we evaluated data from <i>N</i> = 268 healthy controls and <i>N</i> = 519 mild cognitive impairment subjects. Despite being a significant risk factor, amyloid positivity was not associated with clinical progression in the majority (≥60%) of subj ...[more]